全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
华西医学  2012 

不同分子分型乳腺浸润性导管癌中的P53、表皮生长因子受体及Ki-67的表达及意义

, PP. 1349-1353

Keywords: 乳腺肿瘤,,导管,浸润性,免疫表型分型,P53,表皮生长因子受体,人类表皮生长因子受体2,Ki-67

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的 探讨不同分子分型乳腺浸润性导管癌手术病例标本中P53、表皮生长因子受体(EGFR)和Ki-67的表达及临床意义。方法 采用免疫组织化学链霉菌抗生物素蛋白-过氧化物酶连接法法对2010年1月-2011年7月446例乳腺浸润性导管癌患者标本进行分子分型,并同时检测其P53、EGFR、Ki-67等的表达。结果 P53和Ki-67在人类表皮生长因子受体2(HER2)过表达型、基底细胞样型、未分类型中的表达明显强于管腔A型及管腔B型(P<0.05);HER2过表达型和未分类型中的EGFR表达明显强于管腔A型及管腔B型(P<0.05)。结论 在使用雌激素受体、c-erbB-2等指标对浸润性导管癌进行分子分型时同时检测P53、EGFR及Ki-67等标记物,有助于更加精准的评估肿瘤的生物学行为及预后,对靶向药物的个体化治疗提供参考和疗效预测有重要意义。

References

[1]  [ 4 ] Demonty G, Bernard-Marty C, Puglisi F, et al. Progress and new standards of care in the management of HER-2 positive breast cancer[J]. Eur J Cancer, 2007, 43(3): 497-509.
[2]  [ 5 ] 林敏, 陈忠清, 包芸, 等. 乳腺浸润性导管癌分子亚型与临床病理特征及预后的关系[J]. 中华病理杂志, 2010, 39(6): 372-376.
[3]  [ 6 ] 袁中玉, 王树森, 朱美琴, 等. 不同分子亚型乳腺癌的临床特征和预后[J]. 中华肿瘤杂志, 2008, 30(6): 456-461.
[4]  [ 7 ] Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients[J]. Breast Cancer Res, 2006, 8(4): R34.
[5]  [ 8 ] Shirley SH, Rundhaug JE, Tian J, et al. Transcriptional regulation of estrogen receptor-alpha by P53 in human breast cancer cells[J]. Cancer Res, 2009, 69(16): 3405-3414.
[6]  [ 9 ] Mao XY, Fan CF, Zheng HC, et al. P53 nuclear accumulation and ER alpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women [J]. J Exp Clin Cancer Res, 2010, 29(8): 112.
[7]  [ 1 ] Elston CW, Ellis IO. Classification of malignant breast disease[M]// Elston CW, Ellis IO. The breast. Systemic pathology. 3rd ed. Edinburgh: Churchill Livingstone, 1998: 239-247.
[8]  [ 2 ] 唐平, 魏兵, Hicks DG, 等. 乳腺癌的分子分类及其临床应用[J]. 中华病理学杂志, 2009, 38(1): 13-17.
[9]  [ 3 ] Setiawan VW, Monroe KR, Wilkens LR, et al. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study[J]. Am J Epidemiol, 2009, 169(10): 1251-1259.
[10]   曾敏. survivin 在乳腺癌中的表达及其与P53基因的关系[J]. 中华实用诊断与治疗杂志, 2009, 23(12): 1181-1183.
[11]   Yuen PM, Ng PS, Leung PL, et al. Outcome in laparoscopic management of persistent adnexal mass during the second trimester of the second trimester of pregnancy[J]. Surg Endosc, 2004, 18(9): 1354-1357.
[12]   Hanprasertpong J, Tungsinmunkong K, Chichareon S, et al. Correlation of P53 and Ki-67 (MIB-1) expressions with clinicopathological feat ures and prognos is of early stage cervical squamous cell carcinomas[J]. J Obstet Gynaecol Res, 2010, 36(3): 572-580.
[13]   Tzaida O, Gogas H, Dafni U, et al. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy[J]. Oncology, 2007, 72(5-6): 388-396.
[14]   Wu M, Jung L, Zhou J, et al. Dissecting genetic requirements of human breast tumorigenes is in a tissue transgenic model of human breast cancer in mice[J]. Proc Natl Acad Sci USA, 2009, 106(17): 7022-7077.
[15]   Zhang Y, Opresko L, Shankaran H, et al. HER/ErbB receptorin teractions and signaling patterns in human mammary epithelialcells[J]. BMC Cell Biol, 2009, 10: 78-80.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133